NeoTract Inc., a company dedicated to find innovative and clinically feasible solutions to unmet medical needs in the field of urology, received a major boost from the National Institute for Health and Care Excellence (NICE) with an announcement that NeoTract’s minimally invasive technology to treat benign prostate hyperplasia, the UroLift System, was efficient both diagnostically and economically when compared to conventional surgical procedures and post-operative maintenance.
Research and analysis carried out by NICE officials showed that using UroLift could save the NHS as much as £286 ($443) per patient per day. This was hugely significant keeping in mind that BPH cases pose an economic burden of up to £180 million ($279M) annually, with 60% of these costs incurred in secondary care as a result of post-operative management and further complications caused thereby. Coming to clinical benefits of the same, the technology was efficient in lowering Lower Urinary Tract Symptoms (LUTS) and complications, simultaneously preserving the sexual functionality of an individual, previously a major threat posed by surgical techniques like Transurethral Tesection of the Prostate (TURP) and Holmium Laser Enucleation of the Prostate (HoLEP). This coupled with the fact that it significantly reduced a patient’s stay in the hospital and was adaptable to day-surgery procedures under local anaesthesia, made the technology a landmark achievement for NeoTract.
The NICE report suggested that the UroLift System “should be considered as an alternative to current surgical procedures for use in a day-case setting in men with lower urinary tract symptoms of benign prostatic hyperplasia who are aged 50 years and older and who have a prostate of less than 100 ml.” The NHS also made sufficient arrangements for hospitals using this technology to improve patient-care and post-operative maintenance costs.
A triumphant Dave Amerson, President and CEO, NeoTract, Inc. was quoted saying “Both of these announcements independently, as well as the recent inclusion of UroLift into the European Association of Urology Guidelines, further support the clinical and economic value of this game-changing technology. We now expect that the tariff change coupled with this very supportive NICE advice will mean that most, if not all, UK hospitals can choose to offer UroLift in the near future.”